Hepatocellular carcinoma (HCC) has poor prognosis, even after curative resection. Early
recurrence after curative treatment is a major cause of the poor prognosis. Pathologic factors
such as vessel invasion, satellite nodule, size of tumor and pathologic grade are prognostic
factors predicting early recurrence and poor prognosis. We share our experience of two
case
s which both showed early recurrence after curative hepatic resection, but eventually
demonstrated different prognosis. Since the most common cause of death after potentially
curative treatment is tumor recurrence, suppression of tumor recurrence might be linked
to survival gain. Currently, there is no adjuvant therapy for HCC endorsed by international
guidelines. However, recent studies have shown that antiviral treatment for hepatitis B virusrelated
HCC and immunotherapy using autologous cytokine-induced killer cell reduced
HCC recurrence. Further study is needed to select patients who will benefit from adjuvant
treatments.